TENX (Tenax Therapeutics) Total Assets: $123.18 Mil (As of Mar. 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $15.49
! 3 Warning Signs
View Full Analysis

What is Tenax Therapeutics Total Assets?

Tenax Therapeutics TENX +16.42% 22 Total Assets is $123.18 Mil as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Tenax Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $123.18 Mil.

During the past 12 months, Tenax Therapeutics's average Total Assets Growth Rate was 622.70% per year. During the past 3 years, the average Total Assets Growth Rate was 73.30% per year. During the past 5 years, the average Total Assets Growth Rate was 96.70% per year. During the past 10 years, the average Total Assets Growth Rate was -14.70% per year.

During the past 13 years, Tenax Therapeutics's highest 3-Year average Total Assets Growth Rate was 207.50%. The lowest was -80.70%. And the median was 17.00%.

Total Assets is connected with ROA %. Tenax Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -55.29%. Total Assets is also linked to Revenue through Asset Turnover. Tenax Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.


Tenax Therapeutics  (NAS:TENX) Total Assets Explanation

Total Assets is connected with ROA %.

Tenax Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-62.864/( (104.227+123.178)/ 2 )
=-62.864/113.7025
=-55.29 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Tenax Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (104.227+123.178)/ 2 )
=0/113.7025
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Tenax Therapeutics Total Assets Related Terms


Tenax Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics Total Assets Chart

Tenax Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.99 3.41 11.69 96.69 104.23

Tenax Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.06 105.86 102.81 104.23 123.18
TENX
22GF Score
Tenax Therapeutics Inc TENX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Tenax Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=97.071+7.156
=104.23

Tenax Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=114.692+8.486
=123.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $123.18 Mil mean?
Tenax Therapeutics (TENX) has a Total Assets of $123.18 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' Total Assets too high?
Tenax Therapeutics' current Total Assets is $123.18 Mil. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Total Assets compare to RCKT and AVIR?
Tenax Therapeutics' Total Assets of $123.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current Total Assets is $123.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Total Assets of $123.18 Mil. The current Total Assets is $123.18 Mil. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Total Assets is $123.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.49
Price